Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer

By Kenny F.S.  

Breast Cancer Research and Treatment, Vol. 65, Iss. 2, 2001-01 ,pp. : 135-144

Springer Publishing Company

Access to resources Recommend Favorite

Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 73, Iss. 2, 2002-05 ,pp. : 161-175

Springer Publishing Company

Access to resources Recommend Favorite

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer

By Reijm E.  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 387-394

Springer Publishing Company

Access to resources Recommend Favorite

A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women

By                

Oncology Letters, Vol. 2, Iss. 4, 2011-01 ,pp. : 653-658

Spandidos Publications

Access to resources Recommend Favorite

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

By Gökmen-Polar Yesim   Toroni Rachel   Hocevar Barbara   Badve Sunil   Zhao Qianqian   Shen Changyu   Bruckheimer Elizabeth   Kinch Michael   Miller Kathy  

Breast Cancer Research and Treatment, Vol. 127, Iss. 2, 2011-06 ,pp. : 375-384

Springer Publishing Company

Access to resources Recommend Favorite